NEWS: 公告在東京證券交易所JASDAQ標準市場新上市

市場調查報告書

鈣化防禦症(Calciphylaxis)- 市場洞察,流行病學,市場預測 ∼2027年

Calciphylaxis Market Insight, Epidemiology and Market Forecast - 2030

出版商 DelveInsight Business Research LLP 商品編碼 736665
出版日期 按訂單生產 內容資訊 英文 150 Pages
商品交期: 10個工作天內
價格
鈣化防禦症(Calciphylaxis)- 市場洞察,流行病學,市場預測 ∼2027年 Calciphylaxis Market Insight, Epidemiology and Market Forecast - 2030
出版日期: 按訂單生產內容資訊: 英文 150 Pages
簡介

本報告提供鈣化防禦症(Calciphylaxis)市場相關調查,總括性彙整疾病概要,患者背景,主要7國罹患數的預測(今後10年份),新藥概要,診斷指南,治療藥物別的市場規模,市場成長要素·障礙,競爭情形等調查。

目錄

第1章 重要洞察

第2章 鈣化防禦症:市場概要

  • 市場佔有率(實際成果值)
  • 市場佔有率(預測值)
  • 市場佔有率:治療藥物別(實際成果值)
  • 市場佔有率:治療藥物別(預測值)

第3章 鈣化防禦症:疾病背景和概要

  • 簡介
  • 臨床症狀
  • 病理生理學
  • 臨床分類
  • 風險要素
  • 診斷
    • 鑑別診斷
    • 切片檢查
    • X光掃描檢驗·生物標記
    • 實驗室評估

第4章 流行病學和患者人口

  • 主要的觀察

第5章 主要7國的罹患數

第6章 鈣化防禦症的流行病學:各國

  • 美國
    • 前提和根據
    • 整體罹患數
    • 罹患數:性別
    • 罹患數:各年齡
  • 主要歐洲5國
  • 德國
    • 前提和根據
    • 整體罹患數
    • 罹患數:性別
    • 罹患數:各年齡
  • 法國
    • 前提和根據
    • 整體罹患數
    • 罹患數:性別
    • 罹患數:各年齡
  • 義大利
    • 前提和根據
    • 整體罹患數
    • 罹患數:性別
    • 罹患數:各年齡
  • 西班牙
    • 前提和根據
    • 整體罹患數
    • 罹患數:性別
    • 罹患數:各年齡
  • 英國
    • 前提和根據
    • 整體罹患數
    • 罹患數:性別
    • 罹患數:各年齡
  • 日本
    • 前提和根據
    • 整體罹患數
    • 罹患數:性別
    • 罹患數:各年齡

第7章 治療流程,現行治療,醫療行為

第8章 未滿足需求

第9章 新藥

  • 重要的交叉競賽
  • 硫代硫酸鈉:Hope Pharmaceuticals
    • 產品說明
    • 其他開發活動
    • 臨床開發
    • 安全性和有效性
    • 產品簡介
  • SNF472:Sanifit

第10章 停產產品

  • 硫代硫酸鈉:Luitpold Pharmaceuticals
    • 產品說明
    • 臨床開發
    • 產品簡介

第11章 主要7國市場分析

  • 主要的觀察
  • 市場規模
  • 市場規模:治療藥物別

第12章 美國市場預測

  • 美國的市場規模
    • 整體市場規模
    • 市場規模:治療藥物別

第13章 主要歐洲5國市場預測

  • 德國的市場規模
    • 整體市場規模
    • 市場規模:治療藥物別
  • 法國的市場規模
    • 整體市場規模
    • 市場規模:治療藥物別
  • 義大利的市場規模
    • 整體市場規模
    • 市場規模:治療藥物別
  • 西班牙的市場規模
    • 整體市場規模
    • 市場規模:治療藥物別
  • 英國的市場規模
    • 整體市場規模
    • 市場規模:治療藥物別

第14章 日本市場預測

  • 日本的市場規模
    • 整體市場規模
    • 市場規模:治療藥物別

第15章 市場成長要素

第16章 市場障礙

第17章 附錄

  • 調查方法

第18章 DelveInsight的服務內容

第19章 免責聲明

第20章 關於DelveInsight

目錄
Product Code: DIMI0379

DelveInsight's "Calciphylaxis - Market Insights, Epidemiology, and Market Forecast-2030" report delivers an in-depth understanding of the Calciphylaxis, historical and forecasted epidemiology as well as the Calciphylaxis market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

The Calciphylaxis market report provides current treatment practices, emerging drugs, Calciphylaxis market share of the individual therapies, current and forecasted Calciphylaxis market Size from 2017 to 2030 segmented by seven major markets. The Report also covers current Calciphylaxis treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assesses the underlying potential of the market.

Geography Covered

  • The United States
  • EU5 (Germany, France, Italy, Spain, and the United Kingdom)
  • Japan

Study Period: 2017-2030

Calciphylaxis Disease Understanding and Treatment Algorithm

The DelveInsight Calciphylaxis market report gives a thorough understanding of the Calciphylaxis by including details such as disease definition, symptoms, causes, pathophysiology, diagnosis and treatment.

Diagnosis

This segment of the report covers the detailed diagnostic methods or tests for Calciphylaxis.

Treatment

It covers the details of conventional and current medical therapies available in the Calciphylaxis market for the treatment of the condition. It also provides Calciphylaxis treatment algorithms and guidelines in the United States, Europe, and Japan.

Calciphylaxis Epidemiology

The Calciphylaxis epidemiology division provide insights about historical and current Calciphylaxis patient pool and forecasted trend for every seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsight report also provides the diagnosed patient pool and their trends along with assumptions undertaken.

Key Findings

The disease epidemiology covered in the report provides historical as well as forecasted Calciphylaxis epidemiology scenario in the 7MM covering the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom), and Japan from 2017 to 2030.

Country Wise- Calciphylaxis Epidemiology

The epidemiology segment also provides the Calciphylaxis epidemiology data and findings across the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.

Calciphylaxis Drug Chapters

Drug chapter segment of the Calciphylaxis report encloses the detailed analysis of Calciphylaxis marketed drugs and late stage (Phase-III and Phase-II) pipeline drugs. It also helps to understand the Calciphylaxis clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases.

Marketed Drugs

The report provides the details of the marketed product available for Calciphylaxis treatment.

Calciphylaxis Emerging Drugs

The report provides the details of the emerging therapies under the late and mid-stage of development for Calciphylaxis treatment.

Calciphylaxis Market Outlook

The Calciphylaxis market outlook of the report helps to build the detailed comprehension of the historic, current, and forecasted Calciphylaxis market trends by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand of better technology.

This segment gives a thorough detail of Calciphylaxis market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on annual cost of therapy, inclusion and exclusion criteria's, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.

According to DelveInsight, Calciphylaxis market in 7MM is expected to change in the study period 2017-2030.

Key Findings

This section includes a glimpse of the Calciphylaxis market in 7MM.

The United States Market Outlook

This section provides the total Calciphylaxis market size and market size by therapies in the United States.

EU-5 Countries: Market Outlook

The total Calciphylaxis market size and market size by therapies in Germany, France, Italy, Spain, and the United Kingdom is provided in this section.

Japan Market Outlook

The total Calciphylaxis market size and market size by therapies in Japan is also mentioned.

Calciphylaxis Drugs Uptake

This section focusses on the rate of uptake of the potential drugs recently launched in the Calciphylaxis market or expected to get launched in the market during the study period 2017-2030. The analysis covers Calciphylaxis market uptake by drugs; patient uptake by therapies; and sales of each drug.

This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allow the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

Calciphylaxis Pipeline Development Activities

The report provides insights into different therapeutic candidates in Phase II, and Phase III stage. It also analyses Calciphylaxis key players involved in developing targeted therapeutics.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing, patent details and other information for Calciphylaxis emerging therapies.

Reimbursement Scenario in Calciphylaxis

Approaching reimbursement proactively can have a positive impact both during the late stages of product development and well after product launch. In a report, we take reimbursement into consideration to identify economically attractive indications and market opportunities. When working with finite resources, the ability to select the markets with the fewest reimbursement barriers can be a critical business and price strategy.

KOL- Views

To keep up with current market trends, we take KOLs and SME's opinion working in Calciphylaxis domain through primary research to fill the data gaps and validate our secondary research. Their opinion helps to understand and validate current and emerging therapies treatment patterns or Calciphylaxis market trend. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the market and the unmet needs.

Competitive Intelligence Analysis

We perform Competitive and Market Intelligence analysis of the Calciphylaxis Market by using various Competitive Intelligence tools that include - SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies etc. The inclusion of the analysis entirely depends upon the data availability.

Scope of the Report

  • The report covers the descriptive overview of Calciphylaxis, explaining its causes, signs and symptoms, pathophysiology, diagnosis and currently available therapies
  • Comprehensive insight has been provided into the Calciphylaxis epidemiology and treatment in the 7MM
  • Additionally, an all-inclusive account of both the current and emerging therapies for Calciphylaxis are provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape
  • A detailed review of Calciphylaxis market; historical and forecasted is included in the report, covering drug outreach in the 7MM
  • The report provides an edge while developing business strategies, by understanding trends shaping and driving the global Calciphylaxis market

Report Highlights

  • In the coming years, Calciphylaxis market is set to change due to the rising awareness of the disease, and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market
  • The companies and academics are working to assess challenges and seek opportunities that could influence Calciphylaxis R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition
  • Major players are involved in developing therapies for Calciphylaxis. Launch of emerging therapies will significantly impact the Calciphylaxis market
  • A better understanding of disease pathogenesis will also contribute to the development of novel therapeutics for Calciphylaxis
  • Our in-depth analysis of the pipeline assets across different stages of development (Phase III and Phase II), different emerging trends and comparative analysis of pipeline products with detailed clinical profiles, key cross-competition, launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities

Calciphylaxis Report Insights

  • Patient Population
  • Therapeutic Approaches
  • Calciphylaxis Pipeline Analysis
  • Calciphylaxis Market Size and Trends
  • Market Opportunities
  • Impact of upcoming Therapies

Calciphylaxis Report Key Strengths

  • 11 Years Forecast
  • 7MM Coverage

Calciphylaxis Epidemiology Segmentation

  • Key Cross Competition
  • Highly Analyzed Market
  • Drugs Uptake

Calciphylaxis Report Assessment

  • Current Treatment Practices
  • Unmet Needs
  • Pipeline Product Profiles
  • Market Attractiveness
  • Market Drivers and Barriers

Key Questions

Market Insights:

  • What was the Calciphylaxis market share (%) distribution in 2017 and how it would look like in 2030?
  • What would be the Calciphylaxis total market size as well as market size by therapies across the 7MM during the forecast period (2017-2030)?
  • What are the key findings pertaining to the market across 7MM and which country will have the largest Calciphylaxis market size during the forecast period (2017-2030)?
  • At what CAGR, the Calciphylaxis market is expected to grow in 7MM during the forecast period (2017-2030)?
  • What would be the Calciphylaxis market outlook across the 7MM during the forecast period (2017-2030)?
  • What would be the Calciphylaxis market growth till 2030, and what will be the resultant market Size in the year 2030?
  • How would the market drivers, barriers and future opportunities affect the market dynamics and subsequent analysis of the associated trends?

Epidemiology Insights:

  • What is the disease risk, burden and unmet needs of the Calciphylaxis?
  • What is the historical Calciphylaxis patient pool in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
  • What would be the forecasted patient pool of Calciphylaxis in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
  • What will be the growth opportunities in the 7MM with respect to the patient population pertaining to Calciphylaxis?
  • Out of all 7MM countries, which country would have the highest prevalent population of Calciphylaxis during the forecast period (2017-2030)?
  • At what CAGR the population is expected to grow in 7MM during the forecast period (2017-2030)?
  • Current Treatment Scenario, Marketed Drugs and Emerging Therapies:
  • What are the current options for the Calciphylaxis treatment, along with the approved therapy?
  • What are the current treatment guidelines for the treatment of Calciphylaxis in the USA, Europe, and Japan?
  • What are the Calciphylaxis marketed drugs and their MOA, regulatory milestones, product development activities, advantages, disadvantages, safety and efficacy, etc.?
  • How many companies are developing therapies for the treatment of Calciphylaxis?
  • How many therapies are developed by each company for Calciphylaxis treatment?
  • How many are emerging therapies in mid-stage, and late stage of development for Calciphylaxis treatment?
  • What are the key collaborations (Industry - Industry, Industry - Academia), Mergers and acquisitions, licensing activities related to the Calciphylaxis therapies?
  • What are the recent novel therapies, targets, mechanisms of action and technologies developed to overcome the limitation of existing therapies?
  • What are the clinical studies going on for Calciphylaxis and their status?
  • What are the key designations that have been granted for the emerging therapies for Calciphylaxis?
  • What are the global historical and forecasted market of Calciphylaxis?

Reasons to buy

  • The report will help in developing business strategies by understanding trends shaping and driving the Calciphylaxis market
  • To understand the future market competition in the Calciphylaxis market and Insightful review of the key market drivers and barriers
  • Organize sales and marketing efforts by identifying the best opportunities for Calciphylaxis in the US, Europe (Germany, Spain, Italy, France, and the United Kingdom) and Japan
  • Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors
  • Organize sales and marketing efforts by identifying the best opportunities for Calciphylaxis market
  • To understand the future market competition in the Calciphylaxis market

Table of Contents

1. Key Insights

2. Executive Summary of Calciphylaxis

3. Competitive Intelligence Analysis for Calciphylaxis

4. Calciphylaxis: Market Overview at a Glance

  • 4.1. Calciphylaxis Total Market Share (%) Distribution in 2017
  • 4.2. Calciphylaxis Total Market Share (%) Distribution in 2030

5. Calciphylaxis: Disease Background and Overview

  • 5.1. Introduction
  • 5.2. Sign and Symptoms
  • 5.3. Pathophysiology
  • 5.4. Risk Factors
  • 5.5. Diagnosis

6. Patient Journey

7. Calciphylaxis Epidemiology and Patient Population

  • 7.1. Epidemiology Key Findings
  • 7.2. Assumptions and Rationale: 7MM
  • 7.3. Epidemiology Scenario: 7MM
    • 7.3.1. Calciphylaxis Epidemiology Scenario in the 7MM (2017-2030)
  • 7.4. United States Epidemiology
    • 7.4.1. Calciphylaxis Epidemiology Scenario in the United States (2017-2030)
  • 7.5. EU-5 Country-wise Epidemiology
    • 7.5.1. Germany Epidemiology
      • 7.5.1.1. Calciphylaxis Epidemiology Scenario in Germany (2017-2030)
    • 7.5.2. France Epidemiology
      • 7.5.2.1. Calciphylaxis Epidemiology Scenario in France (2017-2030)
    • 7.5.3. Italy Epidemiology
      • 7.5.3.1. Calciphylaxis Epidemiology Scenario in Italy (2017-2030)
    • 7.5.4. Spain Epidemiology
      • 7.5.4.1. Calciphylaxis Epidemiology Scenario in Spain (2017-2030)
    • 7.5.5. United Kingdom Epidemiology
      • 7.5.5.1. Calciphylaxis Epidemiology Scenario in the United Kingdom (2017-2030)
    • 7.5.6. Japan Epidemiology
      • 7.5.6.1. Calciphylaxis Epidemiology Scenario in Japan (2017-2030)

8. Treatment Algorithm, Current Treatment, and Medical Practices

  • 8.1. Calciphylaxis Treatment and Management
  • 8.2. Calciphylaxis Treatment Algorithm

9. Unmet Needs

10. Key Endpoints of Calciphylaxis Treatment

11. Marketed Products

  • 11.1. List of Marketed Products in the 7MM
  • 11.2. Drug Name: Company Name
    • 11.2.1. Product Description
    • 11.2.2. Regulatory Milestones
    • 11.2.3. Other Developmental Activities
    • 11.2.4. Pivotal Clinical Trials
    • 11.2.5. Summary of Pivotal Clinical Trial

List to be continued in report

12. Emerging Therapies

  • 12.1. Key Cross
  • 12.2. Drug Name: Company Name
    • 12.2.1. Product Description
    • 12.2.2. Other Developmental Activities
    • 12.2.3. Clinical Development
    • 12.2.4. Safety and Efficacy
    • 12.2.5. Product Profile

List to be continued in report

13. Calciphylaxis: Seven Major Market Analysis

  • 13.1. Key Findings
  • 13.2. Calciphylaxis Market Size in 7MM
  • 13.3. Calciphylaxis Market Size by Therapies in the 7MM

14. Attribute analysis

15. 7MM: Market Outlook

  • 15.1. United States: Market Size
    • 15.1.1. Calciphylaxis Total Market Size in the United States
    • 15.1.2. Calciphylaxis Market Size by Therapies in the United States
  • 15.2. EU-5 countries: Market Size and Outlook
  • 15.3. Germany Market Size
    • 15.3.1. Calciphylaxis Total Market Size in Germany
    • 15.3.2. Calciphylaxis Market Size by Therapies in Germany
  • 15.4. France Market Size
    • 15.4.1. Calciphylaxis Total Market Size in France
    • 15.4.2. Calciphylaxis Market Size by Therapies in France
  • 15.5. Italy Market Size
    • 15.5.1. Calciphylaxis Total Market Size in Italy
    • 15.5.2. Calciphylaxis Market Size by Therapies in Italy
  • 15.6. Spain Market Size
    • 15.6.1. Calciphylaxis Total Market Size in Spain
    • 15.6.2. Calciphylaxis Market Size by Therapies in Spain
  • 15.7. United Kingdom Market Size
    • 15.7.1. Calciphylaxis Total Market Size in the United Kingdom
    • 15.7.2. Calciphylaxis Market Size by Therapies in the United Kingdom
  • 15.8. Japan Market Outlook
    • 15.8.1. Japan Market Size
    • 15.8.2. Calciphylaxis Total Market Size in Japan
    • 15.8.3. Calciphylaxis Market Size by Therapies in Japan

16. Access and Reimbursement Overview of Calciphylaxis

17. KOL Views

18. Market Drivers

19. Market Barriers

20. Appendix

  • 20.1. Bibliography
  • 20.2. Report Methodology

21. DelveInsight Capabilities

22. Disclaimer

23. About DelveInsight

List of Tables

  • Table 1 : 7MM Calciphylaxis Epidemiology (2017-2030)
  • Table 2 : 7MM Calciphylaxis Diagnosed and Treatable Cases (2017-2030)
  • Table 3 : Disease% Epidemiology in the United States (2017-2030)
  • Table 4 : Calciphylaxis Diagnosed and Treatable Cases in the United States (2017-2030)
  • Table 5 : Calciphylaxis Epidemiology in Germany (2017-2030)
  • Table 6 : Calciphylaxis Diagnosed and Treatable Cases in Germany (2017-2030)
  • Table 7 : Calciphylaxis Epidemiology in France (2017-2030)
  • Table 8 : Calciphylaxis Diagnosed and Treatable Cases in France (2017-2030)
  • Table 9 : Calciphylaxis Epidemiology in Italy (2017-2030)
  • Table 10 : Calciphylaxis Diagnosed and Treatable Cases in Italy (2017-2030)
  • Table 11 : Calciphylaxis Epidemiology in Spain (2017-2030)
  • Table 12 : Calciphylaxis Diagnosed and Treatable Cases in Spain (2017-2030)
  • Table 13 : Calciphylaxis Epidemiology in the UK (2017-2030)
  • Table 14 : Calciphylaxis Diagnosed and Treatable Cases in the UK (2017-2030)
  • Table 15 : Calciphylaxis Epidemiology in Japan (2017-2030)
  • Table 16 : Calciphylaxis Diagnosed and Treatable Cases in Japan (2017-2030)
  • Table 17 : Drug Name, Clinical Trials by Recruitment status
  • Table 18 : Drug Name, Clinical Trials by Zone
  • Table 19 : Total Seven Major Market Size in USD, Million (2017-2030)
  • Table 20 : Region-wise Market Size in USD, Million (2017-2030)
  • Table 21 : 7MM-Market Size by Therapy in USD, Million (2017-2030)
  • Table 22 : United States Market Size in USD, Million (2017-2030)
  • Table 23 : United States Market Size by Therapy in USD, Million (2017-2030)
  • Table 24 : Germany Market Size in USD, Million (2017-2030)
  • Table 25 : Germany Market Size by Therapy in USD, Million (2017-2030)
  • Table 26 : France Market Size in USD, Million (2017-2030)
  • Table 27 : France Market Size by Therapy in USD, Million (2017-2030)
  • Table 28 : Italy Market Size in USD, Million (2017-2030)
  • Table 29 : Italy Market Size by Therapy in USD, Million (2017-2030)
  • Table 30 : Spain Market Size in USD, Million (2017-2030)
  • Table 31 : Spain Market Size by Therapy in USD, Million (2017-2030)
  • Table 32 : United Kingdom Market Size in USD, Million (2017-2030)
  • Table 33 : United Kingdom Market Size by Therapy in USD, Million (2017-2030)
  • Table 34 : Japan Market Size in USD, Million (2017-2030)
  • Table 35 : Japan Market Size by Therapy in USD, Million (2017-2030)

List of Figures

  • Figure 1 : 7MM Calciphylaxis Epidemiology (2017-2030)
  • Figure 2 : 7MM Calciphylaxis Diagnosed and Treatable Cases (2017-2030)
  • Figure 3 : Calciphylaxis Epidemiology in the United States (2017-2030)
  • Figure 4 : Calciphylaxis Diagnosed and Treatable Cases in the United States (2017-2030)
  • Figure 5 : Calciphylaxis Epidemiology in Germany (2017-2030)
  • Figure 6 : Calciphylaxis Diagnosed and Treatable Cases in Germany (2017-2030)
  • Figure 7 : Calciphylaxis Epidemiology in France (2017-2030)
  • Figure 8 : Calciphylaxis Diagnosed and Treatable Cases in France (2017-2030)
  • Figure 9 : Calciphylaxis Epidemiology in Italy (2017-2030)
  • Figure 10 : Calciphylaxis Diagnosed and Treatable Cases in Italy (2017-2030)
  • Figure 11 : Calciphylaxis Epidemiology in Spain (2017-2030)
  • Figure 12 : Calciphylaxis Diagnosed and Treatable Cases in Spain (2017-2030)
  • Figure 13 : Calciphylaxis Epidemiology in the UK (2017-2030)
  • Figure 14 : Calciphylaxis Diagnosed and Treatable Cases in the UK (2017-2030)
  • Figure 15 : Calciphylaxis Epidemiology in Japan (2017-2030)
  • Figure 16 : Calciphylaxis Diagnosed and Treatable Cases in Japan (2017-2030)
  • Figure 17 : Drug Name, Clinical Trials by Recruitment status
  • Figure 18 : Drug Name, Clinical Trials by Zone
  • Figure 19 : Total Seven Major Market Size in USD, Million (2017-2030)
  • Figure 20 : Region-wise Market Size in USD, Million (2017-2030)
  • Figure 21 : 7MM-Market Size by Therapy in USD, Million (2017-2030)
  • Figure 22 : United States Market Size in USD, Million (2017-2030)
  • Figure 23 : United States Market Size by Therapy in USD, Million (2017-2030)
  • Figure 24 : Germany Market Size in USD, Million (2017-2030)
  • Figure 25 : Germany Market Size by Therapy in USD, Million (2017-2030)
  • Figure 26 : France Market Size in USD, Million (2017-2030)
  • Figure 27 : France Market Size by Therapy in USD, Million (2017-2030)
  • Figure 28 : Italy Market Size in USD, Million (2017-2030)
  • Figure 29 : Italy Market Size by Therapy in USD, Million (2017-2030)
  • Figure 30 : Spain Market Size in USD, Million (2017-2030)
  • Figure 31 : Spain Market Size by Therapy in USD, Million (2017-2030)
  • Figure 32 : United Kingdom Market Size in USD, Million (2017-2030)
  • Figure 33 : United Kingdom Market Size by Therapy in USD, Million (2017-2030)
  • Figure 34 : Japan Market Size in USD, Million (2017-2030)
  • Figure 35 : Japan Market Size by Therapy in USD, Million (2017-2030)